多纳非尼效果好不好 多纳非尼靶向药多少钱一盒进入医保了吗( 二 )


4. Cainap C, Qin S, Huang WT, et al: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial. J Clin Oncol 33:172-179, 2015.
5. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34, 2009.
6. Kudo M, Finn RS, Qin S, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 391:1163-1173, 2018.
7. Ren Z, Zhu K, Kang H, et al: Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol 33:894-900, 2015.
8. Llovet JM, Ricci S, Mazzaferro V: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008.
声明:本资料中涉及的信息仅供参考,请遵从医生或其他医疗卫生专业人士的意见或指导 。

多纳非尼效果好不好 多纳非尼靶向药多少钱一盒进入医保了吗

文章插图